Risk factors for competing non‐cancer mortality after definitive treatment for advanced‐stage head and neck cancer

Kim, Yong Han; Roh, Jong–Lyel; Kim, Sung‐Bae; Choi, Seung‐Ho; Nam, Soon Yuhl; Kim, Sang Yoon

doi:10.1111/odi.12904

Cited by 5 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is some evidence to suggest that comorbidity at diagnosis may influence treatment selection and may constitute an independent risk factor for postsurgical outcomes and cause‐specific mortality in people with head and neck cancer. However, these findings are not consistent throughout the literature with one study failing to demonstrate an association between concurrent comorbid conditions and survival in treatment‐stratified analysis .…”

Section: Discussionmentioning

confidence: 99%

“…First, our list of confounding variables was extensive but it was not exhaustive. For example, anemia at diagnosis and performance status has been reported as potential predictors of survival in people with head and neck cancer 6,9,16,35,43,44 but were not collected in our study. Types and details of comorbid conditions were not recorded.…”

Section: Strength and Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000

et al. 2018

View full text Add to dashboard Cite

Background People with head and neck cancer (HNC) have higher comorbidity levels but it remains unclear if pre-treatment comorbidity is an independent prognosticator in HNC. Methods Survival analyses were performed using data from participants in a UK multicentre cohort study with cancers of the oral cavity (n = 668), oropharynx (n = 1,074) and larynx (n = 530). Survival analyses were incrementally adjusted for age, gender, marital status, income, education, stage, alcohol and smoking. Results After adjusting for demographic, clinical and behavioural confounders, higher baseline comorbidity was associated with reduced overall survival (mild comorbidity HR 1.4, 95% CI 1.1, 1.7; moderate comorbidity HR 1.7, 95% CI 1.3, 2.2; severe comorbidity HR 2.8, 95% CI 1.9, 4.; p-trend<.001). Conclusions Our findings suggest that comorbidity is an independent prognosticator for overall survival in HNC. Comorbid illnesses should be considered in the assessment and treatment planning of people with HNC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Strength and Limitationsmentioning

confidence: 99%

Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Masaoka stage was not specifically recorded, but was assigned based on recorded information instead. In addition, comorbidity score was reported to be significantly associated with other causes of mortality in other cancer types (35,36). However, this variable was not included in SEER database.…”

Section: Discussionmentioning

confidence: 99%

Development of a competing risk nomogram for the prediction of cause-specific mortality in patients with thymoma: a population- based analysis

2021

View full text Add to dashboard Cite

Background: This study was developed to assess the odds of cause-specific mortality and other types of mortality in thymoma patients. In addition, these analyses were leveraged to develop a comprehensive competing risk model-based nomogram capable of predicting cause-specific mortality as a result of thymoma.Methods: Thymoma patients included within the Surveillance, Epidemiology, and End Results (SEER) database from 2004-2016 were identified, and the odds of cause-specific mortality due to thymoma and other forms of mortality for these patients were estimated. In addition, Fine and Gray's proportional subdistribution hazard model was constructed, and a competing risk nomogram was developed using this model that was capable of predicting the odds of 3-, 5-, and 10-year cause-specific mortality in thymoma patients. Results: In total, 1,591 relevant cases in the SEER database were selected for analysis. In this patient cohort, the respective 5-year cumulative incidence rates for cause-specific mortality and mortality attributable to other causes were 12.4% and 8.2%. Variables significantly associated with cause-specific mortality included age, chemotherapy, surgery, and Masaoka stage. Additionally, the odds of other-causespecific mortality rose with increasing patient age, and chemotherapy was correlated with other-causespecific mortality. The competing risk nomogram that was developed exhibited good discriminative ability as a means of predicting cause-specific mortality, as evidenced by a concordance index (C-index) value of 0.84.Calibration curves further revealed excellent consistency between predicted and actual mortality when using this nomogram. Conclusions: In summary, we herein assessed the odds of cause-specific and other-cause-specific mortality among thymoma patients, and we designed a novel nomogram capable of predicting cause-specific mortality for thymoma, providing a promising tool that may be of value in the context of individualized patient prognostic evaluation.

show abstract

“…During the decision-making process that involves patient and caregivers, the surgeons must provide detailed information about the expected advantages and disadvantages of surgery, including ablation and reconstructive surgery. If an elderly patient has advanced stage OSCC, the surgeon must inform them of possible poor prognosis and shorter survival rate than a younger patient 10 , 18 , 30 , 36 . It is necessary to inform the patient that various comorbidities, alcohol consumption, and smoking habit are risk factors for postoperative complications 2 , 10 , 18 , 37 .…”

Section: Patient Decisionmentioning

confidence: 99%

Factors to consider for surgical in elderly patients with oral cancer

Lee

Kim

2021

JKAOMS

View full text Add to dashboard Cite

Risk factors for competing non‐cancer mortality after definitive treatment for advanced‐stage head and neck cancer

Abstract: Old age, comorbidity, and hemoglobin at diagnosis were independent predictors of NCM. The risk factors could be used to predict non-cancer death after definitive treatment for advanced-stage HNC.

Cited by 5 publications

References 42 publications

Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000

Association between comorbidity and survival in head and neck cancer: Results from Head and Neck 5000

Development of a competing risk nomogram for the prediction of cause-specific mortality in patients with thymoma: a population- based analysis

Factors to consider for surgical in elderly patients with oral cancer

Contact Info

Product

Resources

About